TATA NOTICE

NOTICE is hereby given that the Fourth (4th) Annual General Meeting ("AGM") of the Members of TATA MEDICAL AND DIAGNOSTICS LIMITED (the "Company") will be held on Thursday, August 29, 2024, at 03:30 pm (IST) through Video Conferencing ("VC") / Other Audio Visual Means ("OAVM") to transact the following business:

ORDINARY BUSINESS:

1. Adoption of Audited Financial Statements for the Financial Year ended March 31, 2024 and the Reports of the Board of Directors and Auditors thereon

To consider and, if thought fit, to pass, with or without modifications, the following resolution as an **ORDINARY RESOLUTION**:

"RESOLVED that the Audited Financial Statements of the Company for the Financial Year ended March 31, 2024 and the Reports of the Board of Directors and Auditors thereon, as circulated to the Members, be considered and adopted."

2. Appointment of Mr. Banmali Agrawala (DIN 00120029) as a Director, liable to retire by rotation, who has offered himself for re-appointment:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **ORDINARY RESOLUTION**:

"RESOLVED that Mr. Banmali Agrawala (DIN 00120029), who retires by rotation and being eligible for re-appointment, be re-appointed as a Director, liable to retire by rotation."

3. Appointment of Ms. Terri Smith Bresenham (DIN 09111500) as a Director, liable to retire by rotation, who has offered herself for re-appointment:

To consider and if thought fit, to pass, with or without modification(s), the following resolution as an **ORDINARY RESOLUTION**:

"RESOLVED that Ms. Terri Smith Bresenham (DIN 09111500), who retires by rotation and being eligible for re-appointment, be re-appointed as a Director, liable to retire by rotation."

1

SPECIAL BUSINESS:

4. Payment of remuneration to Mr. Girish Krishnamurthy, Chief Executive Officer and

Managing Director of the Company:

To consider and, if thought fit, to pass, with or without modifications, the following resolution

as a Special Resolution:

"RESOLVED that pursuant to the provisions of Sections 197, 198, Schedule V and other

applicable provisions, if any, of the Companies Act, 2013, ("Act"), the Companies (Appointment

and Remuneration of Managerial Personnel) Rules, 2014 and other relevant Rules made

under the Act, as amended from time to time, the consent of the Company be and is hereby

accorded for the payment of remuneration to Mr. Girish Krishnamurthy (DIN 00528186), Chief

Executive Officer and Managing Director (CEO & MD) of the Company in the scale of

Rs.2,94,94,500/- (Rupees Two Crore Ninety-Four Lakh Ninety-Four Thousand and Five

Hundred Only) per annum (including performance incentive) upto a maximum of

Rs.4,00,00,000/- (Rupees Four Crore Only) per annum (including performance incentive) with effect from December 1, 2023 till the date of his current term ending on November 30, 2025,

upon the terms and conditions as detailed in the explanatory statement of the Notice, with the

authority to the Board to revise the remuneration within the said limit from time to time.

RESOLVED FURTHER that approval of the Company be and is hereby accorded to the Board

of Directors of the Company to do all such acts, deeds, matters, and things and to take all such

steps as may be required in this connection including seeking all necessary approvals and to

settle any questions or doubts that may arise in this regard to execute all requisite documents.

applications, returns and writings as may be necessary, proper or desirable to give effect to

this Resolution."

Registered Office:

Army & Navy Building, 148, M G Road

Opposite Kala Ghoda, Fort Mumbai City

MH 400001 INDIA Tel No.: +91 9773780760

Email: Kaushik.biswas@tatamd.com

For and on behalf of the Board of Directors

Kaushik Digitally signed by Kaushik Biswas Date: 2024.08.07 15:15:40 +05'30'

Kaushik Biswas

CIN:U33100MH2020PLC342509 Website:www.tatamd.com, Head Legal, Corporate Affairs

Mumbai, June 26, 2024

& Company Secretary ACS 14240



NOTES:

- 1. In view of the global outbreak of the Covid-19 pandemic, the Ministry of Corporate Affairs ("MCA") has vide its General Circular No. 20/2020 dated May 5, 2020 in relation to "Clarification" on holding of annual general meeting (AGM) through video conferencing (VC) or other audio visual means (OAVM)" read with General Circulars No. 14/ 2020, 17/ 2020, 33/2020 and 39/2020 dated April 8, 2020, April 13, 2020, September 28, 2020 and December 31, 2020 respectively, in relation to "Clarification on passing of ordinary and special resolutions by companies under the Companies Act, 2013 and the Rules made thereunder on account of the threat posed by Covid-19", General Circulars No. 02/2021, 21/2021, 02/2022, 10/2022 and 09/2023 dated January 13, 2021, December 14, 2021, May 5, 2022, December 28, 2022 and September 25, 2023 respectively (collectively referred to as the "MCA Circulars") permitted the holding of Annual General Meeting ("AGM") through VC / OAVM, without the physical presence of the Members at a common venue. In compliance with the provisions of the Companies Act, 2013 ("Act") and MCA Circulars, the AGM of the Company is being held through VC / OAVM on Thursday, August 29, 2024, at 03:30 pm (IST). The deemed venue for the 4th AGM will be the Registered Office of the Company i.e. Army & Navy Building, 148, M G Road Opposite Kala Ghoda, Fort, Mumbai Maharashtra 400001 INDIA.
- 2. PURSUANT TO THE PROVISIONS OF THE ACT, A MEMBER ENTITLED TO ATTEND AND VOTE AT THE AGM IS ENTITLED TO APPOINT A PROXY TO ATTEND AND VOTE ON HIS/HER BEHALF AND THE PROXY NEED NOT BE A MEMBER OF THE COMPANY. SINCE THIS AGM IS BEING HELD PURSUANT TO THE MCA CIRCULARS THROUGH VC OR OAVM, THE REQUIREMENT OF PHYSICAL ATTENDANCE OF MEMBERS HAS BEEN DISPENSED WITH. ACCORDINGLY, IN TERMS OF THE MCA CIRCULARS, THE FACILITY FOR APPOINTMENT OF PROXIES BY THE MEMBERS WILL NOT BE AVAILABLE FOR THIS AGM AND HENCE THE PROXY FORM, ATTENDANCE SLIP AND ROUTE MAP OF AGM ARE NOT ANNEXED TO THIS NOTICE.
- 3. Corporate Members intending to appoint their authorized representatives pursuant to Sections 112 and 113 of the Act, as the case may be, to attend the AGM through VC or OAVM are requested to send a certified copy of the Board Resolution to the Company Secretary by e-mail at kaushik.biswas@tatamd.com.
- 4. The attendance of the Members attending the AGM through VC/OAVM will be counted for the purpose of reckoning the quorum under Section 103 of the Act.



- 5. The relevant details, pursuant to Secretarial Standards on General Meetings issued by the Institute of Company Secretaries of India (ICSI), in respect of Directors seeking appointment/re-appointment at this AGM are also enclosed as Annexure I. Requisite declarations have been received from Director(s) for seeking re-appointment.
- 6. The Members can join the AGM in the VC/OAVM mode 15 minutes before and 15 minutes after the scheduled time of the commencement of the Meeting by following the procedure mentioned in the Notice.
- 7. In line with the MCA Circular dated May 5, 2020 and January 13, 2021, the Notice of the AGM along with the Annual Report 2023 24 is being sent only through electronic mode to those Members whose email addresses are registered with the Company / Depositories.
- 8. Members who need assistance in connection with using the technology before or during the AGM, may reach out to the Company officials at kaushik.biswas@tatamd.com.
- 9. Since the Company is not required to conduct e-voting, the voting at the meeting shall be conducted through a show of hands, unless a demand for a poll is made by any member in accordance with Section 109 of the Act. In case of a poll on any resolution at the AGM, members are requested to convey their vote by e-mail at kaushik.biswas@tatamd.com
- 10. Members are requested to intimate changes, if any, pertaining to their name, postal address, e-mail address, telephone/mobile numbers, PAN, registering of nomination, power of attorney registration, Bank Mandate details, etc., to the Company Secretary at kaushik.biswas@tatamd.com, quoting their folio no.
- 11. As per the provisions of Section 72 of the Act, the facility for making nomination is available for the Members in respect of the shares held by them. Members who have not yet registered their nomination are requested to register the same by submitting Form No. SH-13, copy enclosed as Annexure II. If a Member desires to cancel the earlier nomination and record a fresh nomination, he/she/it may submit the same in Form SH-14. Members are requested to submit the said form to the Company at kaushik.biswas@tatamd.com quoting your folio no.
- 12. The format of the Register of Members prescribed by the MCA under the Act requires the Company to record additional details of Members, including their PAN details, e-mail address, bank details for payment of dividend etc. Members holding shares in physical form are requested to submit the filled in form to the Company at its Registered Office address at Army

TATA

& Navy Building, 148, M G Road Opposite Kala Ghoda, Fort, Mumbai Maharashtra 400001

INDIA in physical mode, after restoring normalcy or in electronic mode at

<u>kaushik.biswas@tatamd.com</u>, as per instructions mentioned in the form.

13. During the 4th AGM, Members may access the electronic copy of the Register of Directors

and Key Managerial Personnel and their shareholding maintained under Section 170 of the Act

and the Register of Contracts and Arrangements in which Directors are interested maintained

under Section 189 of the Act by writing to the Company on kaushik.biswas@tatamd.com

14. Members who wish to inspect the relevant documents referred to in the Notice can send

an email to the Company Secretary at kaushik.biswas@tatamd.com up to the conclusion of

this Meeting.

15. Members who would like to express their views or ask questions during the AGM may raise

the same at the meeting or send them in advance (mentioning their name and folio no.), at

least 3 days prior to the date of the AGM at kaushik.biswas@tatamd.com

16. To prevent fraudulent transactions, Members are advised to exercise due diligence and

notify the Company of any change in address or demise of any Member as soon as possible.

17. To support the 'Green Initiative', Members who have not yet registered their email

addresses are requested to register the same with the Company in case the shares are held

by them in physical form.

18. The Company has appointed NSDL Database Management Limited (NDML) as its

Registrar and Transfer Agent (RTA) to render securities registry and other allied services

thereto.

Details of NDML/RTA are given as follows;

Name : NSDL Database Management Limited

Address : 4th Floor, Trade World A Wing, Kamala Mills Compound

Senapati Bapat Marg, Lower Parel, Mumbai – 400 013

Contact Person : Mr. Sachin Shinde

Contact details : 022 4914 2597 (D), 022 4914 2700 (B), 9870455759 (M);

Fax : 022 49142503

Email ID : <u>sachin.shinde@nsdl.co.in</u>

TATA MEDICAL AND DIAGNOSTICS LIMITED

Registered Office Army & Navy Building 148 M G Road Opp Kala Ghoda Fort Mumbai 400001

5



Website : <u>www.ndml-nsdl.co.in</u>

- 19. The shareholders may initiate for conversion of their physical shares (physical share certificate) into dematerialized shares (to hold said shares in DEMAT Form).
- 20. Process for registering email addresses to receive this Notice of AGM and Annual Report electronically:

Registration of e-mail address permanently with Company: Members are requested to register the same with the Company, in respect of physical holding, by writing to them at kaushik.biswas@tatamd.com. Further, those Members who have already registered their e-mail addresses are requested to keep their e-mail addresses validated/updated with the Company to enable servicing of notices/documents/Annual Reports and other communications electronically to their e-mail address in the future.

Registered Office:

For and on behalf of the Board of Directors

Army & Navy Building, 148, M G Road
Opposite Kala Ghoda, Fort Mumbai City
MH 400001 INDIA Tel No.: +91 9773780760

Email: Kaushik.biswas@tatamd.com

Kaushik Digitally signed by Kaushik Biswas Date: 2024.08.07 15:16:25 +05'30'

Kaushik Biswas

CIN:U33100MH2020PLC342509 Website: www.tatamd.com, Head Legal, Corporate Affairs

Mumbai, June 26, 2024

& Company Secretary ACS 14240

EXPLANATORY STATEMENT PURSUANT TO SECTION 102 OF THE COMPANIES ACT, 2013:

In conformity with the provisions of Section 102 of the Companies Act, 2013, the following Explanatory Statement sets out all material facts in respect of Item No. 4.

ITEM NO. 4:

Mr. Girish Krishnamurthy, (DIN 00528186), was the First Director of the Company under the provisions of the Articles of Association of the Company with effect from the date of the incorporation of the Company i.e. July 23, 2020.

The Shareholders of the Company had at the 1st Annual General Meeting held on July 6, 2021, appointed Mr. Girish Krishnamurthy as a Chief executive Officer and Managing Director (hereinafter CEO & MD) for a period of 5 (five) years effective from December 1, 2020 to

TATA

November 30, 2025 and approved the payment of Remuneration of Rs.2,50,00,000 (Rupees Two Crore Fifty Lakh Only) per annum (including performance incentive subject to the approval of the Board) upto a maximum of Rs.4,00,00,000 (Rupees Four Crore Only) per annum (including performance incentive subject to the approval of the Board), for a period of 3 years i.e. from December 1, 2020, to November 30, 2023.

Pursuant to Sections 197, 198, Schedule V and applicable provisions of the Companies Act 2013 and the relevant Rules made thereunder, the Board has in its meeting held on January 30, 2024 ratified and approved the revision and payment of the remuneration of Rs.2,94,94,500/- (Rupees Two Crore Ninety-Four Lakh Ninety-Four Thousand Five Hundred Only) per annum including performance incentive (subject to the approval of the Board) to Mr. Girish Krishnamurthy for the Financial Year (FY) 2023 – 24 i.e. effective from April 1, 2023, to March 31, 2024.

Further, the Board in its meeting held on June 26, 2024 has approved the payment of remuneration to Mr. Girish Krishnamurthy of an amount of Rs.3,05,56,302 (Rupees Three Crore Five Lakh Fifty-Six Thousand Three Hundred and Two Only) per annum including performance incentive (subject to the approval of the Board) upto a maximum amount of Rs.4,00,00,000/- (Rupees Four Crore Only) per annum including performance incentive (subject to the approval of the Board), effective from April 1, 2024 till the date of his current term ending on November 30, 2025, with the authority to the Board to revise the remuneration within the said limit from time to time.

A brief profile of Mr. Girish Krishnamurthy as follows:

Mr. Girish Krishnamurthy is the Managing Director and CEO at Tata Medical and Diagnostics Ltd. (Tata MD). In addition, he steered several companies as a Board of Director, Advisor and Mentor.

With over three decades of rich multi-domain and entrepreneurial experience across key sectors like Healthcare, Software Products, Retail, IT Services, Skill Development, Education and Manufacturing, Mr. Girish Krishnamurthy has successfully led multiple transformational initiatives globally.

Over the last 8 years, Mr. Girish Krishnamurthy has played a key role in various initiatives. He has conceptualized and executed innovative solutions to complex problems in the areas

of Healthcare and Medical and Diagnostics. He has successfully implemented large

Healthcare experiments in primary, secondary, tertiary, and cancer care.

Mr. Girish Krishnamurthy has been recognized for his transformative thinking and has been

felicitated with several awards. He has been a member of several national government

committees. He has authored multiple papers on technology and business strategies. An

enthusiastic speaker at various industry forums, Mr. Girish Krishnamurthy also mentors

several start-up businesses.

Mr. Girish Krishnamurthy holds an MBA from the University of Texas, Dallas, and a graduate

in Electrical Engineering and in Mathematics from the University of Madras.

The remuneration of managerial personnel is governed by the provisions of Section 197 read

with Schedule V of the Companies Act, 2013 (hereinafter the "Act").

Tata Medical and Diagnostics Limited (the "Company") being in the nascent stage of its

operations, the Company may not have profits, or its profits may be inadequate for the initial

years to compensate and pay the remuneration to the managerial personnel (hereinafter the

"Managerial Remuneration"), the said managerial remuneration needs to be paid in

compliance with Sections II and III of Part II of Schedule V of the Act.

Pursuant to Sections 197, 198 and all other applicable provisions including Sections II and III

of Part II of Schedule V of the Act and the Companies (Appointment and Remuneration of

Managerial Personnel) Rules, 2014 [including any statutory modification(s) or re-

enactment(s) thereof for the time being in force], the proposal with respect to payment of

remuneration to Mr. Girish Krishnamurthy is now being placed before the Members at the

Annual General Meeting for their consideration and approval by way of Special Resolution as

set out at Item no. 4 of the Notice.

The main terms and conditions of the payment of remuneration to Mr. Girish Krishnamurthy

as CEO & MD are given below:

Remuneration:

A. Remuneration period: From December 1, 2023 till the date his current term ending on

November 30, 2025.

TATA MEDICAL AND DIAGNOSTICS LIMITED

8



B. **Remuneration amount**: Rs.2,94,94,500/- (Rupees Two Crore Ninety-Four Lakh Ninety-Four Thousand Five Hundred Only) per annum including performance incentive upto a maximum of Rs.4,00,00,000/- (Rupees Four Crore Only) per annum including performance incentive. Remuneration shall be ascertained on a pro-rata basis if is to be payable for any part of the year/financial year.

The performance incentive shall be subject to due performance review and approval by the Board and payable after the relevant Annual Accounts adopted by the Board.

The Explanatory Statement may be considered as a written Memorandum setting out terms, conditions, and limits of remuneration of Mr. Girish Krishnamurthy in terms of Section 190 of the Act.

During the Financial Year 2024, Four Board Meetings of the Company were held, and Mr. Girish Krishnamurthy attended all the said Meetings.

Statement as required under Section II of Part II of Schedule V to the Companies Act, 2013 giving details in respect of payment of remuneration to Mr. Krishnamurthy as CEO & MD of the Company is as follows;

General Information:

- 1. Nature of Industry: Healthcare
- 2. **Date of commencement of Commercial Production**: The Company started its commercial production in September 2020.
- 3. In the case of new companies, the expected date of commencement of activities as per the object approved by financial institutions appearing in the prospectus: The date of commencement of activities is September 2020.

4. Financial Performance based on given indicators:

Rs. Crore

Particulars	Current FY 2024	Previous FY 2023	Previous FY 2022
Turnover	13.22	13.65	60.58
Profit/(Loss) Before tax	(94.05)	(125.79)	(146.68)
Profit/(Loss) After Tax	(142.45)	(125.79)	(108.39)

TATA

5. Foreign Investments or Collaborations, if any: NIL

II. Information about the appointee:

1. Background details: Provided herein above under the brief profile of Mr. Girish

Krishnamurthy.

2. **Past remuneration**: CTC Rs.2,94,94,500/- p.a.

3. Recognition or award: Mr. Girish Krishnamurthy is recognized for his work and has won

several awards along his journey. He has authored leading papers on technology and

business strategies and has mentored several innovative start-up businesses across the

world.

4. Job Profile and his suitability: Mr. Girish Krishnamurthy is the CEO & MD and is in-

charge of the operations of the Company. Considering the overall exposure and experience

of Mr. Krishnamurthy in the diversified areas and responsibilities shouldered by him, he is

suitable for the position.

5. **Remuneration proposed**: As mentioned above in the Explanatory Statement.

6. Comparative Remuneration profile with respect to industry, size of the Company,

profile of the position and person (in case of expatriates, the relevant details would be

w. r. t. the country of his origin): Considering the size of the Company, the industry

benchmarks, experience and the responsibilities shouldered by the appointee, the proposed

remuneration payable to Mr. Krishnamurthy is commensurate with the remuneration paid to

similar appointee in other companies.

7. Pecuniary Relationship directly or indirectly with the Company or relationship with

the managerial personnel, if any: Except for the proposed remuneration Mr. Krishnamurthy

does not have any pecuniary relationship directly or indirectly with the Company or

managerial personnel or Key Managerial Personnel (KMP) of the Company.

TATA MEDICAL AND DIAGNOSTICS LIMITED



III. Other information:

1	Reasons for the inadequacy of profits	Tata MD was incorporated on July 23,
		2020, and is at a nascent stage of its
		Operation
2	Steps taken or proposed to be taken for	To scale up Operations and Sales and
	improvement	Services
3	Expected increase in productivity and	As the Company is a newly incorporated
	profits in measurable terms	entity and its operations domain/product
		(s) range widely depend on Science,
		Technology, Research and Innovation,
		etc. currently it is unable to state the
		expected increase in productivity and
		profits in measurable terms

Brief resume of Mr. Girish Krishnamurthy, nature of his expertise in specific functional areas, disclosure of relationships between directors inter-se, name of other companies in which he holds directorships and memberships/chairmanships of Board Committees, shareholding in the Company, the number of Meetings of the Board attended during the year, as stipulated under Secretarial Standard on General Meetings issued by the Institute of Company Secretaries of India are stated herein in the Annexure – I.

Company Secretary of the Company certifies herewith that there is no default of any payment to any secured creditor(s)/Bank(s)/term lender(s) w.r.t. the credit facility(s) availed by the Company in its business operations.

Except Mr. Girish Krishnamurthy and his relatives, none of the other Directors and Key Managerial Personnel of the Company and their respective relatives, are concerned or interested, in the Resolution set out in Item No. 4 of the Notice.

The Board recommends the Special Resolution set out at Item No. 4 of the Notice for the approval of the Members.

Registered Office:

For and on behalf of the Board of Directors

Army & Navy Building, 148, M G Road Opposite Kala Ghoda, Fort Mumbai City MH 400001 INDIA Tel No.: +91 9773780760

Kaushik Digitally signed by Kaushik Biswas Biswas Date: 2024.08.07

Email: Kaushik.biswas@tatamd.com

Kaushik Biswas

CIN:U33100MH2020PLC342509 Website:www.tatamd.com, Head Legal, Corporate Affairs Mumbai, June 26, 2024

& Company Secretary ACS 14240



Annexure - I

The details of Directors seeking appointment/revision in the remuneration at the 4^{th} Annual General Meeting pursuant to SS – 2 Secretarial Standard on General Meetings issued by The Institute of Company Secretaries of India, are furnished below: -

Name of Director	Mr. Banmali	Ms. Terri Smith	Mr. Girish
	Agrawala	Bresenham	Krishnamurthy
DIN	00120029	09111500	00528186
Date of birth	30.04.1963	16.12.1960	18.09.1965
Age	61 years	63 years	58 years
Date of appointment	23.07.2020	23.03.2021	23.07.2020
Expertise in specific	A veteran in Energy,	Passionate about	Healthcare
Professional areas	Infrastructure, Defence	healthcare and global	Transformation
	& Aerospace domain.	health issues and has	through digital
	Engineering,	devoted more than 30	innovation, Sales,
	Technology and	years to the field.	Services, Marketing,
	Business Management	Started her career as	and Operations etc.
		a clinical chemist,	Engineering &
		joined GE as an	Technology and
		"Edison Engineer" and	Business Management
		progressed through	
		engineering and	
		product management	
		roles in Magnetic	
		Resonance Imaging,	
		Computed.	
		Tomography and	
		Positron Emission	
		Tomography. Also led	
		GE's US Women's	
		Health business, and	
		global businesses	
		including GE	
		Ultrasound and GE	
		Molecular Imaging.	
		i	



Qualification	Mechanical	Master's degree in	MBA from the
Engineering Graduate		Biomedical	University of Texas,
	from Mangalore	Engineering from the	Dallas and a Graduate
	University and an		in Electrical
	alumnus of the		Engineering and
	Advanced	and Bachelor's in Medical Technology	Mathematics from the
	Management Program	from the University of	University of Madras
	of Harvard Business	Tennessee, USA	omvereny er maarae
	School	10111100000, 0071	
List of other Companies in	i. Tata Housing	Narayana	Tata Indian Institute of
which Directorship held as	Development	Hrudayalaya Limited	Skills
on March 31, 2024	Company Ltd	Tiradayalaya Elifilica	OKIII3
(except foreign	ii. Tata Realty and		
company(s))	Infrastructure Ltd		
oompany(o))	iii. Tata Advanced		
	Systems Ltd		
	iv. Tata Electronics		
	Private Limited		
	v. Tata Boeing		
	Aerospace Limited		
	vi. Tata Lockheed		
	Martin Aerostructures		
	Limited		
	vii. Tata Sikorsky		
	Aerospace Limited		
	viii. Pratham		
	Education Foundation		
Chairman/ Member of the	Please refer below	Narayana Hrudayalaya	NIL
Committee of Board of	Table – I	Limited:	
other Companies as on		i. Chairperson:	
March 31, 2024 (except		Nomination and	
foreign company(s))		Remuneration	
		Committee	
		ii. Member: Corporate	
		Social Responsibility	
		Committee	



Terms and conditions of	Liable to retire by	Liable to retire by	Term: 5 years, liable to
Appointment/remuneration	rotation	rotation	retire by rotation.
			Please refer Item No. 4
			of the Explanatory
			Statement
Remuneration last drawn	NIL	Rs.2,00,000/-	CTC Rs.2,94,94,500/-
(including sitting fees, if any)			
Remuneration proposed	NIL	NIL	Please refer to the
to be paid			explanatory statement
			annexed to the Notice
			of the 4 th AGM
Number of Meetings of the	4 out of 4 meetings	2 out of 4 meetings	4 out of 4 meetings
Board attended during the	held during his tenure	held during his tenure	held during his tenure
period under review			
Number of Shares held in	1 (One) Equity share	NIL	NIL
the Company as at March	held jointly with Tata		
31, 2024	Sons Private Limited		
Relationship between	No	No	No
Directors inter-se			

Registered Office:

For and on behalf of the Board of Directors

Army & Navy Building, 148, M G Road
Opposite Kala Ghoda, Fort Mumbai City
MH 400001 INDIA Tel No.: +91 9773780760

Email:Kaushik.biswas@tatamd.com

Kaushik Digitally signed by Kaushik Biswas Date: 2024.08.07 15:16:55 +05'30'

Kaushik Biswas

CIN:U33100MH2020PLC342509 Website:www.tatamd.com, Head Legal, Corporate Affairs

Mumbai, June 26, 2024

& Company Secretary ACS 14240



Table - I

Mr. Banmali Agrawala: Committee Memberships in Public Companies

Sr.	Name of the Company	Name of Committee	Chairman/
No.			Member
1	Tata Housing Development	1) Nomination & Remuneration	1) Member
	Company Limited	Committee	
		2) Securities Allotment Committee	2) Chairman
2	Tata Realty and	1) Nomination & Remuneration	1) Member
	Infrastructure Limited	Committee	
		2) Securities and Allotment Committee	2) Member
3	Tata Advanced Systems	1) Audit Committee	1) Chairman
	Limited	2) Nomination & Remuneration	2) Chairman
		Committee	
4	Tata Electronics Private	1) Treasury Committee	1) Member
	Limited		
5	Tata Boeing Aerospace	1) Nomination and Remuneration	1) Member
	Limited	Committee	
		2) Corporate Social Responsibility	2) Member
		Committee	
6	Tata Sikorsky Aerospace	1)Audit Committee	1) Chairman
	Limited	2) Nomination and Remuneration	2) Member
		Committee	
		3)Corporate Social Responsibility	3) Member
		Committee	
7	Tata Lockheed Martin	1)Nomination and Remuneration	1) Member
	Aerostructures Limited	Committee	
		2)Corporate Social Responsibility	2) Chairman
		Committee	

Registered Office:

For and on behalf of the Board of Directors

Army & Navy Building, 148, M G Road Opposite Kala Ghoda, Fort Mumbai City MH 400001 INDIA Tel No.: +91 9773780760

Email: Kaushik.biswas@tatamd.com

Mumbai, June 26, 2024

CIN:U33100MH2020PLC342509 Website: www.tatamd.com, Head Legal, Corporate Affairs

& Company Secretary ACS 14240

Kaushik Digitally signed by Kaushik

Kaushik Biswas

Biswas Biswas Date: 2024.08.07 15:17:22 +05'30'

TATA MEDICAL AND DIAGNOSTICS LIMITED



Annexure II

Form No. SH-13

Nomination Form [Pursuant to Section 72 of the Companies Act, 2013 and Rule 19(1) of the Companies (Share Capital and Debentures) Rules 2014]

To,				
TATA MEDICAL AND DIA	AGNOSTICS	LIMITED		
Army & Navy Building, 148	8, M G Road			
Opposite Kala Ghoda, For		ty MH 400001 IND	A.	
I/We				
the holder(s) of the sec	urities partic	ulars of which are	e given hereunde	er wish to make
nomination and do hereby	nominate the	e following persons	in whom shall ves	st, all the rights in
respect of such securities	in the event o	of my/our death.		
(1) PARTICULARS OF TH	IE SECURITI	ES (in respect of w	hich nomination is	s being made)
Nature of securities	Folio No	No. of securities	Certificate No.	Distinctive No.
(2) PARTICULARS OF NO	OMINEE/S —			
(a) Name:				
(b) Date of Birth:				
(c) Father's/Mother's/Spou	ıse's name:			
(d) Occupation:				
(e) Nationality:				
(f) Address:				
(g) E-mail id:				
(h) Relationship with the s	ecurity holder	r:		
(3) IN CASE NOMINEE IS	A MINOR			
(a) Date of birth:				
(b) Date of attaining major	itv:			

(c) Name of guardian:



(d) Address of guardian:
Name:
Address:
Name of the Security
Holder(s):
Signature:
Witness with name and address: